Willekens, Christophe

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell

COVID-19 Clinical Research StudiesInflammation biomarkers and pathways

Cited by 834

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine

Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Cited by 220

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Somervaille, T., Salamero, O., Montesinos, P., Willekens, C., Perez Simon, J. A., Pigneux, A., Recher, C., Popat, R., Molinero, C., Mascaro, C., et al. (2016) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 46

AG-221, an oral, selective, first-in-class, potent IDH2-R140Q mutant inhibitor, induces differentiation in a xenotransplant model

Quivoron, C., David, M., Straley, K., Travins, J., Kim, H., Chen, Y., Zhu, D., Saada, V., Bawa, O., Opolon, P., et al. (2014) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 19